New drugs targeting calcitonin gene-related peptide for the management of migraines

References

• Wells-Gatnik WD, Wences Chirino TY, Onan FN, et al. Emerging experimental drugs in clinical trials for migraine: observations and key talking points. Expert Opin Investig Drugs. 2023;32(8):761–771. doi: 10.1080/13543784.2023.2254691
   PubMed Web of Science ®Google Scholar
• Tana C, Giamberardino MA, Cipollone F. microRNA profiling in atherosclerosis, diabetes, and migraine. Ann Med. 2017;49(2):93–105. doi: 10.1080/07853890.2016.1226515
   PubMed Web of Science ®Google Scholar
• Wang T. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain. 2023;24(1):79. doi: 10.1186/s10194-023-01619-9
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of Headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. doi: 10.1177/0333102413485658
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. doi: 10.1186/s10194-022-01402-2
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Lifting the burden: the global campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi: 10.1186/s10194-020-01208-0
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology. 1997 Mar;48(3 Suppl 3):S4–9. PMID: 9071263. doi: 10.1212/wnl.48.3_suppl_3.4s
   PubMed Web of Science ®Google Scholar
• Begasse de Dhaem O, Sakai F. Migraine in the workplace. eNeurologicalsci. 2022 Jun 6;27:100408. doi: 10.1016/j.ensci.2022.100408
   PubMedGoogle Scholar
• Delussi M, Vecchio E, Libro G, et al. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC neurol. 2020;20(1):256. doi: 10.1186/s12883-020-01839-5
   PubMed Web of Science ®Google Scholar
• Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5. doi: 10.1038/s41572-022-00415-0
   PubMed Web of Science ®Google Scholar
• Affaitati G, Martelletti P, Lopopolo M, et al. Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic Headache. Pain Pract. 2017 Mar;17(3):392–401. doi: 10.1111/papr.12461
   PubMed Web of Science ®Google Scholar
• Tana C, Cipollone F, Giamberardino MA. New therapeutic options for migraine. Curr Pharm Des. 2023;29(25):1964–1966. doi: 10.2174/1381612829666230821092238
   PubMed Web of Science ®Google Scholar
• Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–1142. doi: 10.1152/physrev.00034.2013
   PubMed Web of Science ®Google Scholar
• Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of Monoclonal antibodies in migraine. Headache. 2018;58(10):1689–1696. doi: 10.1111/head.13439
   PubMed Web of Science ®Google Scholar
• Irimia P, García-Azorín D, Núñez M, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022;23(1):78. doi: 10.1186/s10194-022-01448-2
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008. doi: 10.1001/jama.2018.4853
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122. doi: 10.1056/NEJMoa1709038
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377(22):2123–2132. doi: 10.1056/NEJMoa1705848
   PubMed Web of Science ®Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e2260. doi: 10.1212/WNL.0000000000007452
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254. doi: 10.1177/0333102420905132
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–e1377. doi: 10.1212/WNL.0000000000009169
   PubMed Web of Science ®Google Scholar
• Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC neurol. 2021;21(1):126. doi: 10.1186/s12883-021-02123-w
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018 Sep 1;75(9):1080–1088. doi: 10.1001/jamaneurol.2018.1212
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454. doi: 10.1177/0333102418779543
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. doi: 10.1212/WNL.0000000000006640
   PubMed Web of Science ®Google Scholar
• Urits I, Yilmaz M, Charipova K, et al. An evidence-based review of galcanezumab for the treatment of migraine. Neurol Ther. 2020;9(2):403–417. doi: 10.1007/s40120-020-00214-3
   PubMed Web of Science ®Google Scholar
• Vydura (rimegepant). last update 2022 Apr. Available from: https://www.ema.europa.eu/en/documents/overview/vydura-epar-medicine-overview_en.pdf
   Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–149. doi: 10.1056/NEJMoa1811090
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51–60. doi: 10.1016/S0140-6736(20)32544-7
   PubMed Web of Science ®Google Scholar
• Boinpally R, Jakate A, Butler M, et al. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2021;10(7):726–733. doi: 10.1002/cpdd.916
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775–785. doi: 10.1016/S0140-6736(23)01049-8
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019 Dec 5;381(23):2230–2241. doi: 10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023 Apr;43(4):3331024231159366. doi: 10.1177/03331024231159366
   Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–217. doi: 10.1016/S1474-4422(22)00517-8
   PubMed Web of Science ®Google Scholar
• Zhang H, Qi JZ, Zhang ZH. Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):81. doi: 10.1186/s10194-023-01625-x
   PubMed Web of Science ®Google Scholar
• Ceriani CEJ, Silberstein SD. Current and emerging pharmacotherapy for menstrual migraine: a narrative review. Expert Opin Pharmacother. 2023;24(5):617–627. doi: 10.1080/14656566.2023.2194487
   PubMed Web of Science ®Google Scholar
• Jiang Y, Huang ZL. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: a narrative review. Medicine (Baltimore). 2022;101(24):e29361. doi: 10.1097/MD.0000000000029361
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Storch E, Overeem LH, et al. Sex hormones and Calcitonin gene-related peptide in women with migraine: a cross-sectional, matched cohort study. Neurology. 2023;100(17):e1825–e1835. doi: 10.1212/WNL.0000000000207114
   PubMed Web of Science ®Google Scholar
• Hugger SS, Do TP, Ashina H, et al. Migraine in older adults. Lancet Neurol. 2023;22(10):934–945. doi: 10.1016/S1474-4422(23)00206-5
   PubMed Web of Science ®Google Scholar
• Muñoz-Vendrell A, Campoy S, Caronna E, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63. doi: 10.1186/s10194-023-01585-2
   PubMed Web of Science ®Google Scholar
• Affaitati G, Costantini R, Tana C, et al. Co-occurrence of pain syndromes. J Neural Transm (Vienna). 2020;127(4):625–646. doi: 10.1007/s00702-019-02107-8
   PubMed Web of Science ®Google Scholar
• Tana C, Azorin DG, Cinetto F, et al. Common clinical and molecular pathways between migraine and Sarcoidosis. Int J Mol Sci. 2023;24(9):8304. doi: 10.3390/ijms24098304
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Martelletti P, et al. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2015;17:28. doi: 10.1186/s10194-016-0619-8
   PubMed Web of Science ®Google Scholar
• Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache syndromes. Curr Opin Neurol. 2023;36(3):168–174. doi: 10.1097/WCO.0000000000001153
   PubMed Web of Science ®Google Scholar
• Korucu RU, Karadağ A, Taş A, et al. Serum Calcitonin gene-related peptide and receptor protein levels in patients with fibromyalgia syndrome: a cross-sectional study. Arch Rheumatol. 2020;35(4):463–467. doi: 10.46497/ArchRheumatol.2020.7783
   PubMed Web of Science ®Google Scholar
• A study to test the effectiveness and safety of fremanezumab on participants with fibromyalgia. last update 2023 Mar. Available from: https://clinicaltrials.gov/study/NCT03965091
   Google Scholar
• Walsh DA, McWilliams DF. CGRP and painful pathologies other than Headache. Handb Exp Pharmacol. 2019;255:141–167.
   PubMedGoogle Scholar
• Schou WS, Ashina S, Amin FM, et al. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18(1):34. doi: 10.1186/s10194-017-0741-2
   PubMed Web of Science ®Google Scholar
• Luo L, Qi W, Zhang Y, et al. Calcitonin gene-related peptide and its receptor plays important role in nociceptive regulation in the arcuate nucleus of hypothalamus of rats with inflammatory pain. Behav Brain Res. 2023;443:114351. doi: 10.1016/j.bbr.2023.114351
   PubMed Web of Science ®Google Scholar
• Urits I, Li N, Bahrun E, et al. An evidence-based review of CGRP mechanisms in the propagation of chronic visceral pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):507–516. doi: 10.1016/j.bpa.2020.06.007
   PubMed Web of Science ®Google Scholar
• Caldarella MP, Giamberardino MA, Sacco F, et al. Sensitivity disturbances in patients with irritable bowel syndrome and fibromyalgia. Am J Gastroenterol. 2006 Dec;101(12):2782–2789. doi: 10.1111/j.1572-0241.2006.00823.x
   PubMed Web of Science ®Google Scholar
• Vecchiet L, Giamberardino MA, Saggini R. Myofascial pain syndromes: clinical and pathophysiological aspects. Clin J Pain. 1991;7(1):16–22. doi: 10.1097/00002508-199108000-00004
   Google Scholar
• Ruscheweyh R, Gossrau G, Dresler T, et al. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache registry. J Headache Pain. 2023;24(1):135. doi: 10.1186/s10194-023-01676-0
   PubMed Web of Science ®Google Scholar
• Manack Adams A, Hutchinson S, Engstrom E, et al. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE study. J Headache Pain. 2023;24(1):102. doi: 10.1186/s10194-023-01622-0
   PubMed Web of Science ®Google Scholar
• Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):133. doi: 10.1186/s10194-022-01502-z
   PubMed Web of Science ®Google Scholar
• Singh A, Gupta D, Sahoo AK. Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med. 2020;2(8):1132–1138. doi: 10.1007/s42399-020-00390-1
   Google Scholar
• Navratilova E, Behravesh S, Oyarzo J, et al. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020;40(9):892–902. doi: 10.1177/0333102420938652
   PubMed Web of Science ®Google Scholar
• Saengjaroentham C, Strother LC, Dripps I, et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain. 2020;143(9):2681–2688. doi: 10.1093/brain/awaa211
   PubMed Web of Science ®Google Scholar
• Siersbæk N, Kilsdal L, Jervelund C, et al. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC neurol. 2023;23(1):254. doi: 10.1186/s12883-023-03302-7
   PubMed Web of Science ®Google Scholar